The optimal preconditioning regimen for platelet-FVIII gene therapy to establish immune tolerance while achieving sustained platelet-FVIII expression is more stringent than that used to achieve sustained platelet-FVIII expression alone in unprimed hemophilia A mice. The gene discussed is F8; the disease is hemophilia A.